Literature DB >> 12757918

Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support.

Hideaki Kato1, Etsuro Orito, Fuminaka Sugauchi, Ryuzo Ueda, Takuya Koshizaka, Shoko Yanaka, Robert G Gish, Fuat Kurbanov, Ruslan Ruzibakiev, Anna Kramvis, Michael C Kew, Nooruddin Ahmad, Mobin Khan, Sadakazu Usuda, Yuzo Miyakawa, Masashi Mizokami.   

Abstract

A genotype-specific probes assay (GSPA) was developed for distinguishing the seven genotypes (A-G) of hepatitis B virus (HBV). Nucleotide (nt) sequences corresponding to preS1 region were amplified by PCR with a primer labeled with biotin, and delivered to eight wells on which complementary sequences specific to one or other genotype had been immobilized. Thereafter, hybridization of HBV DNA sequences amplified from the test serum was detected by colorimetry. When 256 sera from HBV carriers in Bangladesh, Cameroon, Japan, South Africa, USA and Uzbekistan were subjected to GSPA, genotypes were concordant with those of ELISA with monoclonal antibodies to epitopes on preS2-region products in 242 (94.6%) of them; 8 sera (3.1%) were not genotypeable by either method. Cloning analysis confirmed the presence of two distinct HBV genotypes in the seven selected sera with coinfection. There were 7 (2.7%) sera with discordant genotyping results between GSPA and ELISA. When HBV DNA clones propagated from these sera were sequenced and analyzed phylogenetically, the genotypes determined by GSPA were verified. Coinfection with HBV strains of two distinct genotypes was identified by GSPA in 28 (10.9%) sera, while it was suggested by ELISA in only 2 (0.8%) sera. The GSPA method would be particularly useful for detecting the coinfection with distinct HBV genotypes of any clinical relevance, which seems to be more frequent than reported previously.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757918     DOI: 10.1016/s0166-0934(03)00095-8

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

Review 1.  Hepatitis B virus taxonomy and hepatitis B virus genotypes.

Authors:  Stephan Schaefer
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 2.  The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile".

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

Review 3.  Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus.

Authors:  Margaret Littlejohn; Stephen Locarnini; Lilly Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-04       Impact factor: 6.915

4.  Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection.

Authors:  Shigehiko Sainokami; Koichi Abe; Akihiro Sato; Ryujin Endo; Yasuhiro Takikawa; Kazuyuki Suzuki; Hiroaki Okamoto
Journal:  J Gastroenterol       Date:  2007-03-30       Impact factor: 7.527

5.  Geographical and ethnic distribution of the HBV C/D recombinant on the Qinghai-Tibet Plateau.

Authors:  Bin Zhou; Lei Xiao; Zhanhui Wang; Ellen T Chang; Jinjun Chen; Jinlin Hou
Journal:  PLoS One       Date:  2011-04-11       Impact factor: 3.240

6.  Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver.

Authors:  Sung Kwan Bae; Hiroshi Yatsuhashi; Satoru Hashimoto; Yasuhide Motoyoshi; Eisuke Ozawa; Shinya Nagaoka; Seigo Abiru; Atsumasa Komori; Kiyoshi Migita; Minoru Nakamura; Masahiro Ito; Yuzo Miyakawa; Hiromi Ishibashi
Journal:  Med Sci Monit       Date:  2012-12

7.  Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection.

Authors:  C-M Chu; C-C Lin; Y-C Chen; W-J Jeng; S-M Lin; Y-F Liaw
Journal:  Br J Cancer       Date:  2012-10-18       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.